期刊文献+

更昔洛韦注射液联合复方倍他米松注射液治疗带状疱疹的临床研究 被引量:12

Clinical trial of ganciclovir injection combined with compound betamethasone injection in the treatment of herpes zoster
原文传递
导出
摘要 目的观察更昔洛韦注射液联合复方倍他米松注射液治疗带状疱疹患者的临床疗效及安全性。方法将114例带状疱疹患者随机分为对照组和试验组,每组57例。对照组予以更昔洛韦每次150 mg,bid,静脉滴注,5 d后,剂量调整为每次150 mg,qd,静脉滴注,继续治疗3~5 d;试验组在对照组治疗的基础上,予以复方倍他米松注射液1 m L,单次肌内注射。比较2组患者的临床疗效、临床表现缓解时间和后遗神经痛(PHN)发生率,血浆P物质(SP)和β-内啡肽(β-EP)水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的总有效率分别为89.47%(51例/57例)和70.18%(40例/57例),差异有统计学意义(P<0.05)。治疗后,试验组和对照组的止疱时间分别为(4.46±0.68)和(5.88±0.68)d,止痛时间分别为(4.32±0.66)和(7.98±0.13)d,脱痂时间分别为(11.39±1.37)和(15.18±1.91)d,PHN发生率分别为22.81%(13例/57例)和42.11%(24例/57例),SP分别为(59.01±8.03)和(81.32±9.75)ng·L^(-1),β-EP分别为(48.65±5.89)和(42.54±5.26)ng·L^(-1),差异均有统计学意义(均P<0.05)。2组患者的药物不良反应均以恶心呕吐、腹部不适和头痛为主,试验组和对照组的总药物不良反应发生率分别为12.28%和17.54%,差异无统计学意义(P>0.05)。结论更昔洛韦注射液联合复方倍他米松注射液治疗带状疱疹患者的临床疗效确切,其能显著降低PHN发生率,抑制血浆SP表达,促进β-EP分泌,且不增加药物不良反应的发生率。 Objective To observe the clinical efficacy and safety of ganciclovir injection combined with compound betamethasone injection in the treatment of herpes zoster. Methods A total of 114 patients with herpes zoster were randomly divided into control and treatment groups with 57 cases per group. Control group was given ganciclovir 150 mg per time,bid,intravenous drip,and after 5 days,the dose was adjusted to 150 mg per time,qd,intravenous drip for 3 to 5 days. Treatment group received compound betamethasone 1 m L,single intramuscular injection,on the basis of control group. The clinical efficacy,time of clinical performance and the incidence of postherpetic neuralgia( PHN),the levels of substance P( SP) and β-endorphin( β-EP),and adverse drug reactions were compared between two groups. Results After treatment,the total effective rates of treatment and control groups ware 89. 47%( 51 cases/57 cases) and 70. 18%( 40 cases/57 cases) with significant difference( P 0. 05). After treatment,the main indexes in treatment and control groups were compared: herpes stopping time were( 4. 46 ± 0. 68) and( 5. 88 ± 0. 68) d,analgesia time were( 4. 32 ± 0. 66) and( 7. 98 ± 0. 13) d,scabby time were( 11. 39 ± 1. 37) and( 15. 18 ± 1. 91) d,incidences of PHN were 22. 81%( 13 cases/57 cases) and 42. 11%( 24 cases/57 cases),SP were( 59. 01 ± 8. 03)and( 81. 32 ± 9. 75) ng·L^(-1),β-EP were( 48. 65 ± 5. 89) and( 42. 54 ± 5. 26) ng·L^(-1),the differences were statistically significant( all P 0. 05). The adverse drug reactions of two groups were nausea,vomiting,abdominal discomfort and headache. The total incidences of adverse drug reactions in the treatment and control groups were 12. 28%and 17. 54% without significant difference( P 0. 05). Conclusion Ganciclovir injection combined with compound betamethasone injection has a definitive clinical efficacy in the treatment of herpes zoster,which can reduce the incidence of PHN,inhibit the expression level of plasma SP,and promote the secretion of β-EP,without increasing the incidence of adverse drug reactions.
作者 张晓云 康康 王生 ZHANG Xiao-yun;KANG Kang;WANG Sheng(Department of Dermatology,Tangshan Gongren Hospital,Tangshan 063000,Hebei Province,Chin)
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2018年第15期1816-1818,共3页 The Chinese Journal of Clinical Pharmacology
基金 河北省卫生厅课题资助项目(20130478)
关键词 更昔洛韦注射液 复方倍他米松注射液 带状疱疹 安全性 ganciclovir injection compound betamethasone injection herpes zoster safety
  • 相关文献

参考文献3

二级参考文献87

共引文献992

同被引文献125

引证文献12

二级引证文献46

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部